There are currently 2704 clinical trials in Boston, Massachusetts looking for participants to engage in research studies. Trials are conducted at various facilities, including Massachusetts General Hospital, Dana Farber Cancer Institute, Brigham and Women's Hospital and Beth Israel Deaconess Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
NCT06964009
Recruiting
The purpose of this research study is determining the highest dose of the study drug DT2216 in combination with paclitaxel that can be safely and tolerably administered in recurrent ovarian cancer. The names of the study drugs involved in this study are: * DT2216 (a type of proteolysis-targeting chimera degrader of BCL-XL protein) * Paclitaxel (a type of antimicrotubule agent)
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/03/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts +1 locations
Conditions: Ovarian Cancer, Ovarian Carcinoma, Recurrent Ovary Cancer, Recurrent Platinum-Resistant Ovarian Carcinoma
Register for Updates
A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa
NCT06603077
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of AVTX-009 compared with placebo in patients with moderate to severe Hidradenitis Suppurativa (HS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: Clinical Site 1001, Boston, Massachusetts
Conditions: Hidradenitis Suppurativa
Register for Updates
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
NCT06585774
Recruiting
This study will be conducted to compare the efficacy of axatilimab versus placebo in combination with corticosteroids as initial treatment for moderate or severe chronic graft-versus-host disease (cGVHD).
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/02/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Chronic Graft-versus-host-disease
Register for Updates
Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients
NCT06690398
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients aged 5 to 17 years with a primary diagnosis of irritability associated with Autism Spectrum Disorder (ASD) based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Text Revision (DSM-5-TR) and confirmed by the Kiddie Schedule for Affective Disorders and Schizophrenia Present and Lifetime Version (K-SADS-PL).
Gender:
ALL
Ages:
Between 5 years and 17 years
Trial Updated:
07/02/2025
Locations: Clinical Site, Boston, Massachusetts
Conditions: Irritability Associated With Autism Spectrum Disorder
Register for Updates
A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome
NCT06312020
Recruiting
The purpose of this study is to measure the efficacy and safety of HZN-1116 in participants with Sjogren's syndrome (SS).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/02/2025
Locations: Tufts Medical Center - 800 Washington St - PPDS, Boston, Massachusetts
Conditions: Sjogren's Syndrome
Register for Updates
Remote Tai Chi for Knee Osteoarthritis
NCT06384898
Recruiting
The goal of this pragmatic randomized trial is to evaluate the effectiveness of remote Tai Chi to treat knee pain in adults with knee osteoarthritis. The main questions the trial aims to answer are: * Compared to routine care, will patients with Knee OA receiving remote Tai Chi exhibit greater improvement in knee-related pain (WOMAC pain score, primary outcome), pain interference (PROMIS-Pain Interference, secondary outcome), and health-related quality of life at 3 months? * Does remote tai chi... Read More
Gender:
ALL
Ages:
Between 50 years and 100 years
Trial Updated:
07/02/2025
Locations: Tufts Medical Center, Boston, Massachusetts
Conditions: Knee Osteoarthritis
Register for Updates
CardiolRx in Recurrent Pericarditis Following IL-1 Blocker Cessation
NCT06708299
Recruiting
Multi-center, randomized, double-blind, placebo-controlled, phase-3 Trial. Patients with a history of recurrent pericarditis who are being treated with an IL-1 blocker for at least 12 months, scheduled to be discontinued, will be approached for potential trial participation. Double-blind treatment will be initiated 10 - 14 days prior to the last scheduled dose of the IL-1 blocker and continued for 24 weeks. The objective is to assess whether patients who discontinue therapy with an IL-1 blocke... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Recurrent Pericarditis
Register for Updates
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
NCT06388564
Recruiting
This study will be conducted to determine the preliminary efficacy of axatilimab in combination with ruxolitinib and to assess the contribution of axatilimab to the combination treatment effect in participants with cGVHD.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/02/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Chronic Graft-versus-host-disease
Register for Updates
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
NCT06215118
Recruiting
The main purpose of the study is to understand how safe and tolerable is elranatamab when given along with iberdomide. There are 2 parts to this study. Part 1 will look at how safe and tolerable is elranatamab when given with iberdomide. Part 2 will look at the correct amount of this combination that can be given to patients with relapsed or refractory multiple myeloma. Myeloma is a type of cancer that begins in plasma cells (white blood cells that produce antibodies). Refractory means a disea... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Multiple Myeloma
Register for Updates
Using Visual Arrays to Support Understanding of Genetic Risk
NCT06994832
Recruiting
The goal of this study is to understand how people understand risk from genetic testing. The investigators want to understand what visual aid best helps people accurately assess risk. The investigators also want to understand how people relate risk to their health. The main questions the study aims to answer are: 1. Which visual aid most accurately show genetic risk? 2. How do people perceive risk related to genetic test results? 3. What factors are associated with people discussing their resul... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: Boston College, Boston, Massachusetts
Conditions: Decision Aid
Register for Updates
A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration
NCT06660667
Recruiting
This is a Phase 1/Phase 2 multicenter study to evaluate the safety and efficacy of a one-time single-eye intravitreal dose of SAR402663 in participants with neovascular age-related macular degeneration. Participants will be enrolled in one of 2 parts: * In Part I (dose escalation), multiple dose levels of SAR402663 will be evaluated in successive cohorts of participants * In Part II (dose expansion), participants will be randomized to receive one of two dose levels selected based on data from... Read More
Gender:
ALL
Ages:
Between 50 years and 90 years
Trial Updated:
07/02/2025
Locations: Site # 8400009, Boston, Massachusetts
Conditions: Neovascular Age-related Macular Degeneration
Register for Updates
A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease
NCT06826612
Recruiting
The main goal of this study is to evaluate the safety, tolerability, and preliminary efficacy of SPK-10001 in participants with Huntington's Disease.
Gender:
ALL
Ages:
Between 25 years and 65 years
Trial Updated:
07/02/2025
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Huntington Disease
Register for Updates